Market Overview

US Stock Futures Flat Ahead Of Jobless Claims

US Stock Futures Flat Ahead Of Jobless Claims

Pre-open movers

US stock futures traded mostly flat in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average dropped 5.5 points to 17,469.5, while the Standard & Poor's 500 index futures rose 0.40 points to 2,094.15. Futures for the Nasdaq 100 index gained 4.30 points to 4,597.80.

A Peek Into Global Markets

European markets were lower today, with the Spanish Ibex Index falling 0.23 percent, STOXX Europe 600 Index dropping 0.44 percent and German DAX 30 index declining 0.09 percent. French CAC 40 Index slipped 0.04 percent and London's FTSE 100 Index fell 0.38 percent.

In Asian markets, Japan's Nikkei Stock Average rose 0.24 percent, Hong Kong's Hang Seng Index dropped 0.57 percent, China's Shanghai Composite Index slipped 0.89 percent and India's BSE Sensex gained 0.27 percent.

Broker Recommendation
Analysts at Morgan Stanley downgraded Keurig Green Mountain Inc (NASDAQ: GMCR) from Overweight to Equal-weight and lowered the price target from $110.00 to $60.00.

Keurig Green Mountain shares dipped 29.91 percent to $52.55 in pre-market trading.

Breaking news

  • Becton, Dickinson and Co. (NYSE: BDX) reported better-than-expected earnings for its fiscal third quarter and raised its earnings forecast for the full year. To read the full news, click here.
  • AngioDynamics, Inc. (NASDAQ: ANGO) today announce the enrollment of the first patient into the Registry of AngioVac Procedures In Detail (RAPID) Database at University of California-Los Angeles (UCLA) Health in Los Angeles, California. To read the full news, click here.
  • SAGE Therapeutics Inc (NASDAQ: SAGE) today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). To read the full news, click here.
  • Viacom, Inc. (NASDAQ: VIAB) reported in-line earnings for its fiscal third quarter, but the company's revenue missed analysts' estimates. To read the full news, click here.

Posted-In: Morgan Stanley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets


Related Articles (ANGO + BDX)

View Comments and Join the Discussion!

Qualcomm's Atheros Unit to Buy Ikanos for $2.75/Share in Cash

EUR/USD Little Changed